![Greg P. Bertenshaw](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Greg P. Bertenshaw
Geschäftsführer bei BioMarker Strategies LLC
Aktive Positionen von Greg P. Bertenshaw
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BioMarker Strategies LLC
![]() BioMarker Strategies LLC Pharmaceuticals: GenericHealth Technology BioMarker Strategies LLC develops medicines for cancer. It provides cancer diagnostics system for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. The company was founded by Scott Allocco, Kathleen Murphy and Douglas P. Clark in May 2006 and is headquartered in Rockville, MD. | Geschäftsführer | 05.06.2020 | - |
Technik-/Wissenschafts-/F&E-Leiter | 01.12.2011 | - |
Karriereverlauf von Greg P. Bertenshaw
Ehemalige bekannte Positionen von Greg P. Bertenshaw
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | Technik-/Wissenschafts-/F&E-Leiter | - | 07.02.2013 |
Clearant, Inc.
![]() Clearant, Inc. Pharmaceuticals: MajorHealth Technology Clearant, Inc. produces tissue allograft implants, plasma therapies, blood and recombinant products. The company was founded on April 30, 1999 and is headquartered in Orlando, FL. | Direktor/Vorstandsmitglied | 01.01.2002 | 02.01.2004 |
Ausbildung von Greg P. Bertenshaw
The University of Manchester | Undergraduate Degree |
The Pennsylvania State University | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Vereinigtes Königreich | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Correlogic Systems, Inc.
![]() Correlogic Systems, Inc. BiotechnologyHealth Technology Correlogic Systems, Inc. has pioneered the use of pattern recognition technologies for the development of proteomic, metabolomic and genomic based clinical prognostic and clinical diagnostic tests. The company has applied its proprietary software and sample preparation technologies to a wide range of high throughput bioassay platforms, including mass spectrometry, nuclear magnetic resonance spectrometry, nucleic acid arrays, and immunoassays. Correlogic's technologies have a wide range of applications for the creation of disease classification models, biomarker discovery, and new drug discovery processes. Correlogic's research, demonstrating results in cancer and non-cancer disease research, drug discovery, drug response monitoring, bio-security and other applications has been published in 13 peer-reviewed journals. Correlogic is also a clinical laboratory regulated under the Clinical Laboratory Improvement Amendments of 1988, designated to perform high complexity testing. Correlogic has entered into agreements to provide an ovarian cancer testing service in cooperation with the nation's two premier diagnostic laboratories, Quest Diagnostics and Laboratory Corporation of America. | Health Technology |
Clearant, Inc.
![]() Clearant, Inc. Pharmaceuticals: MajorHealth Technology Clearant, Inc. produces tissue allograft implants, plasma therapies, blood and recombinant products. The company was founded on April 30, 1999 and is headquartered in Orlando, FL. | Health Technology |
BioMarker Strategies LLC
![]() BioMarker Strategies LLC Pharmaceuticals: GenericHealth Technology BioMarker Strategies LLC develops medicines for cancer. It provides cancer diagnostics system for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. The company was founded by Scott Allocco, Kathleen Murphy and Douglas P. Clark in May 2006 and is headquartered in Rockville, MD. | Health Technology |
- Börse
- Insiders
- Greg P. Bertenshaw
- Erfahrung